Akero Therapeutics Announces Initiation of Phase 3 Synchrony Outcomes Trial of Efruxifermin in Patients With Compensated Cirrhosis (F4) Due to Mash
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.